Pacific Edge Limited (NZE:PEB)
New Zealand flag New Zealand · Delayed Price · Currency is NZD
0.1010
-0.0010 (-0.99%)
Jul 31, 2025, 4:32 PM NZST
-0.99%
Market Cap81.19M
Revenue (ttm)22.75M
Net Income (ttm)-29.94M
Shares Out811.92M
EPS (ttm)-0.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume322,361
Average Volume421,687
Open0.1010
Previous Close0.1010
Day's Range0.1000 - 0.1010
52-Week Range0.0500 - 0.1850
Beta0.71
RSI46.44
Earnings DateMay 23, 2025

About ShockWave Medical

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; and Cxbladder Monitor, a non-inva... [Read more]

Industry Medical - Diagnostics & Research
Sector Healthcare
Founded 2001
Employees 114
Stock Exchange New Zealand Stock Exchange
Ticker Symbol PEB
Full Company Profile

Financial Performance

In 2024, Pacific Edge's revenue was 22.75 million, a decrease of -9.83% compared to the previous year's 25.23 million. Losses were -29.94 million, 1.36% more than in 2023.

Financial Statements

News

Half Year 2025 Pacific Edge Ltd Earnings Call Transcript

Half Year 2025 Pacific Edge Ltd Earnings Call Transcript

8 months ago - GuruFocus